Tosufloxacin is a fluoroquinolone antibacterial agent. Tosufloxacin is an inhibitor of bacterial DNA gyrase and topoisomerase IV. Tosufloxacin is indicated for the treatment of various infections such as skin, respiratory, urinary, gynecologic, ophthalmologic, otolaryngologic, dental infections. Fluoroquinolones including tosufloxacin have a potential risk of inducing cartilage and joint toxicity in children. It is also associated with severe thrombocytopenia and nephritis, and hepatotoxicity.

Clomocycline is the approved name of a methylol derivative of chlortetracycline. Clomocycline is a tetracycline antibiotic that is commonly prescribed by medical doctors for infections and to treat acne. It may also be used to treat urinary tract infections, gum disease, and other bacterial infections such as gonorrhea and chlamydia. Clomocycline is also used commonly as a prophylactic treatment for infection by Bacillus anthracis (anthrax). It is also effective against Yersinia pestis and malaria and is also prescribed for the treatment of Lyme disease. Clomocycline inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Clomocycline is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane. This drug has been reported to be noticeably free of side-effects such as nausea, vomiting, and diarrhea.

Indium is a rare, soft silvery-white metal. It is used in some manufacturing process, butt here is no known biological role for indium in the human body. Although there are claims that indium increases hormone production, stimulates immune system function, and increases energy, there is no reliable scientific evidence to support such claims. In vitro, indium-III salts appears to have cytotoxic activity against melanoma. Indium cation (Indium-III), when complexed with 8-hydroxyquinoline (oxine), has been employed as a radioactive platelet label for thrombus imaging in animals and man. The short half-life (2.8 d) and high yield of gamma photons of 111In make it ideal for in vitro counting and external imaging. Indium In 111 ProstaScint (Capromab Pendetide) is indicated as a diagnostic imaging agent in newly-diagnosed patients with biopsy-proven prostate cancer, thought to be clinically-localized after standard diagnostic evaluation (eg chest x-ray, bone scan, CT scan, or MRI), who are at high-risk for pelvic lymph node metastases. It is not indicated for patients who are not at high risk. Indium In 111 ProstaScint is also indicated as a diagnostic imaging agent in post-prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic evaluation in whom there is a high clinical suspicion of occult metastatic disease.

Icotinib is an orally available quinazoline-based inhibitor of epidermal growth factor receptor. It selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. The major organ of icotinib metabolism is the liver, with the primarily enzymes being CYP2C19 and CYP3A4 from the cytochrome P450 monooxygenase system. Icotinib Hydrochloride was approved for the treatment of patients with advanced stage Nonsmall cell lung cancer by the State Food and Drug Administration (SFDA) of China. The major drug related adverse reactions of the traditional cytotoxic agents include rash, diarrhea, severe bone marrow suppression, neuropathy, hair loss, and gastrointestinal reactions. Icotinib is under investigation as an active agent against other EGFR mutation-positive cancers, like lung adenocarcinoma, oesophageal cancer, nasopharyngeal cancer and others.

Naphthoquine is an antimalarial drug first synthesized in China in 1986 but which was not developed for clinical use until the late 1990s. This drug now is used in combination for treatment of Plasmodium Falciparum and Malaria. The use of anti-malarial drug combinations with artemisinin or with one of its derivatives is now widely recommended to overcome drug resistance in falciparum as well as vivax malaria. The fixed oral dose artemisinin-naphthoquine combination (ANQ, ARCO™) is a newer artemisinin-based combination (ACT) therapy undergoing clinical assessment.

Sodium glycididazole (CMNA), a nitroimidazole compound that has a radiation-enhancing effect. This drug was studied in the treatment of patients with various tumors, such as non-small-cell lung cancer, esophageal carcinoma. CMNA combined with chemoradiotherapy participated in phase II clinical trials in patients with locally recurrent squamous cell esophageal carcinoma. It was shown, that CMNA improved curative effects without increasing adverse reactions, and significantly increase survival rates of the patients. The precise mechanism of action CMNA is not clear but is known that it acts through downregulation of ATM signaling pathway.

Cu-64 is an isotope of copper with potential use in PET imaging and the targeted radiotherapy of cancer. It has a complex decay scheme, with electron capture, beta-emission and positron emission branches. Cu-64 in the most simple salt form as well as linked to a variety of bioactive molecules can be used as theranostic agents in human malignancies such as prostate, glioblastoma, melanoma, breast cancers) and also diagnosis of human copper-associated diseases such as atherosclerosis, Alzheimer’s etc. There are some examples of investigational Cu-64-based radiopharmaceuticals: Cu-64-ATSM for imaging hypoxia, Cu-64-labeled peptides for tumor-receptor targeting, Cu-64-labeled monoclonal antibodies for targeting tumor antigens, and Cu-64-labeled nanoparticles for cancer targeting.

Dipipanone are indicated for the management of moderate to severe pain in medical and surgical conditions in which morphine may be indicated. Dipipanone is related to methadone and can be substituted for assorted opioids. The severe or irreversible adverse effects of Dipipanone, which give rise to further complications, include hypotension, hypotension, hependence, agranulocytosis, ischemic colitis, generalized chorea, hypersensitivity hepatitis. It may interact badly with monoamine oxidase inhibitors, which are substances found in some antidepressants and other medication.

PR-69 (Doranidazole) is a hypoxic radiosensitizer, and is a derivative of 2-nitroimidazole intended to reduce neurotoxicity due to its blood brain barrier (BBB) impermeability. Several studies have shown that doranidazole has a radiosensitizing effect under hypoxia, both in vitro and in vivo. Based on these studies, a phase III trial of doranidazole against advanced pancreatic cancer was performed; it was demonstrated that treatment with doranidazole following radiation significantly improved the tumor mass reduction rate and extended patient survival. Various results have suggested that doranidazole has promising potential for hypoxia-targeting chemoradiotherapy.